Ozempic maker plans manufacturing blitz as market for the drug is expected to top $100 billion in 2030
Novo Nordisk makes Ozempic and Wegovy, two hit drugs that treat obesity. Supply is a major issue right now, with the firm warning a European regulator it may ration Ozempic.
Novo Nordisk to launch obesity drug Wegovy in Japan in February
Novo Nordisk said on Thursday it will launch its hugely popular Wegovy obesity drug in Japan on Feb. 22 next year.
Novo Nordisk invests $2.3 mln in France to boost output
Danish drug maker Novo Nordisk said on Thursday it would invest more than 16 billion crowns ($2.34 billion) in the expansion of production facilities in Chartres in France.
Macron to unveil 2.1 bln eur Novo Nordisk pharma investment in France
French President Emmanuel Macron will on Thursday inaugurate a 2.1 billion euro ($2.3 billion) investment by Danish pharmaceutical company Novo Nordisk in France, his office said, pitching it as a ...
Weight loss drugs Wegovy and Zepbound to debut in pill form
Popular weight loss drugs Wegovy and Zepbound will soon be available in pill form. Pharmaceutical giants Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) are actively promoting pill versions...
Novo Nordisk Eyes Another Breakout As Weight-Loss Battle Continues
Novo Nordisk stock is Thursday's IBD Stock Of The Day after a study showed weight-loss drug, Wegovy, cut down on heart attacks and strokes.
Wegovy's Sales Potential Could Go Far Beyond Just Weight-Loss Treatment
Wegovy is approved to treat chronic weight management, but it has far more potential in the future. Another indication, for reducing the risk of cardiovascular disease, could be coming in 2024.
Belgium bans use of Ozempic for weight loss until summer
Belgium has decided to temporarily ban the use of Novo Nordisk's diabetes drug Ozempic as a weight loss treatment amid a shortage of the medicine, according to a royal decree published in the count...
Better Growth Stock: Pfizer vs. Novo Nordisk
Pfizer is looking to buy and develop new revenue drivers. Novo Nordisk aims to penetrate a profitable market even more.
How Novo Nordisk's ‘select' study results could shake up the obesity drug space
Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk's ‘select' study and what it means for the obesity drug space.
Novo Nordisk ADRs Climb After Study Suggests Its Wegovy Showed Heart Benefits
American depositary receipts (ADRs) of Novo Nordisk (NVO) edged higher in early trading on Monday after reporting a study showed its flagship diabetes and weight-loss drug, Wegovy, helped reduce ri...
Novo Nordisk Stock Skids — But These Weight-Loss Results Are 'Hard To Ignore'
Novo Nordisk stock slumped Monday despite unveiling promising test results for weight-loss drugs and diabetes development.
Novo Nordisk's (NVO) Wegovy Positive in Cardiovascular Study
Novo Nordisk's (NVO) obesity drug Wegovy shows potential in cardiovascular study beyond the benefits of associated weight loss.
Novo Nordisk's Wegovy could reduce heart risks by 20%
According to a new trial study, Novo Nordisk's (NVO) weight loss drug Wegovy may have the added benefit of cutting down risks tied to cardiovascular complications by at least 20%. Yahoo Finance Liv...
Wegovy predicted to become huge drug as weight loss benefits confirmed
Novo Nordisk (NYSE:NVO) did not disappoint with the latest trial data update of its blockbuster diabetes drug Wegovy, according to analysts at US bank Citi. Full results from the SELECT trial relea...
Related Companies